1. Home
  2. FGEN vs NXPL Comparison

FGEN vs NXPL Comparison

Compare FGEN & NXPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FGEN
  • NXPL
  • Stock Information
  • Founded
  • FGEN 1993
  • NXPL 1997
  • Country
  • FGEN United States
  • NXPL United States
  • Employees
  • FGEN N/A
  • NXPL N/A
  • Industry
  • FGEN Biotechnology: Pharmaceutical Preparations
  • NXPL Telecommunications Equipment
  • Sector
  • FGEN Health Care
  • NXPL Telecommunications
  • Exchange
  • FGEN Nasdaq
  • NXPL Nasdaq
  • Market Cap
  • FGEN 34.5M
  • NXPL 32.5M
  • IPO Year
  • FGEN 2014
  • NXPL N/A
  • Fundamental
  • Price
  • FGEN $0.46
  • NXPL $0.99
  • Analyst Decision
  • FGEN
  • NXPL
  • Analyst Count
  • FGEN 0
  • NXPL 0
  • Target Price
  • FGEN N/A
  • NXPL N/A
  • AVG Volume (30 Days)
  • FGEN 727.9K
  • NXPL 116.9K
  • Earning Date
  • FGEN 02-24-2025
  • NXPL 11-14-2024
  • Dividend Yield
  • FGEN N/A
  • NXPL N/A
  • EPS Growth
  • FGEN N/A
  • NXPL N/A
  • EPS
  • FGEN N/A
  • NXPL N/A
  • Revenue
  • FGEN $180,015,000.00
  • NXPL $66,482,000.00
  • Revenue This Year
  • FGEN $21.91
  • NXPL N/A
  • Revenue Next Year
  • FGEN N/A
  • NXPL N/A
  • P/E Ratio
  • FGEN N/A
  • NXPL N/A
  • Revenue Growth
  • FGEN 16.15
  • NXPL 179.89
  • 52 Week Low
  • FGEN $0.18
  • NXPL $0.71
  • 52 Week High
  • FGEN $2.80
  • NXPL $2.68
  • Technical
  • Relative Strength Index (RSI)
  • FGEN 41.72
  • NXPL 43.47
  • Support Level
  • FGEN $0.46
  • NXPL $0.89
  • Resistance Level
  • FGEN $0.51
  • NXPL $1.08
  • Average True Range (ATR)
  • FGEN 0.04
  • NXPL 0.09
  • MACD
  • FGEN -0.01
  • NXPL -0.01
  • Stochastic Oscillator
  • FGEN 6.59
  • NXPL 25.64

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

About NXPL NextPlat Corp

NextPlat Corp is a global e-commerce and healthcare company. Its e-commerce venues form an effective global network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operate in two segments: e-Commerce Business and Healthcare Business.

Share on Social Networks: